Report
Healthcare Team

Coverage update

To reprioritize resources, we are dropping coverage of AstraZeneca, bioMerieux, GSK, Novartis, Novo Nordisk, Roche, Sanofi, Lysogene and Quantum Genomics.
Underlyings
AstraZeneca PLC ADS

Glaxosmithkline Consumer Nigeria

Lysogene SA

Lysogene SA is a France-based company principally engaged in the bio diagnostics and testing. The Company is focused on the gene therapy biotechnology. The Company develops treatments targeting severe genetic pathologies with central nervous system involvement and high unmet medical needs. It is specialized in the development of intracerebral gene therapy aimed at treating pathologies affecting the central nervous system, which is the main cause of neuro-degenerative disease mortality in children.

Novartis AG

Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.

Novo Nordisk A/S ADS

Zhejiang Satellite Petrochemical (A)

ZHEJIANG SATELLITE PETROCHEMICAL CO.,LTD is a China-based company principally engaged in the research, development, production and sale of chemicals. The Company's main products include propylene, acrylic acid, acrylic ester, acrylic textile emulsion, Super Absorbent Polymer (SAP) and pigment intermediates. The Company is also engaged in chemical transportation business and other businesses. The Company distributes its products in domestic market and to overseas markets.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Healthcare Team

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch